CRISPR stocks continue ascent on Intellia data: Data Byte

Stocks of the three publicly traded CRISPR therapeutics companies with access to the technology’s foundational IP continued their rise throughout the week following the first clinical data for a systemically delivered CRISPR therapy from Intellia on Saturday.

Shares of Intellia Therapeutics Inc. (NASDAQ:NTLA), which gained about $3 billion in market cap on Monday, finished the week up $74.88 (84%) to $163.71, representing a gain of over $5 billion in market cap since last Friday. The company, which now has a market cap of more than $11 billion, followed the data by raising a $690 million follow-on, the largest such offering so far this year on NASDAQ...